Lanean...
SUN-170 Development of Type 1 Diabetes Mellitus on Immune Checkpoint Inhibitor
Introduction: Immune checkpoint inhibitors (ICPi) are used to augment the immune response and have led to improved outcomes in various malignancies. With this enhanced immunologic response comes a spectrum of side effects, known as immune-related adverse events (iRAEs). These are most commonly derma...
Gorde:
| Argitaratua izan da: | J Endocr Soc |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Endocrine Society
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553242/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-170 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|